Search clinical trials for: pramipexole immediate release tablet

Total 782 results

Boehringer Ingelheim

Completed

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Healthy
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Pivotal Study in Advanced Parkinsons Disease Patients

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Boehringer Ingelheim

Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

Parkinson Disease

France, Germany, Netherlands
First Affiliated Hospital of Zhejiang University
Hongguan biological pharmaceutical co.

Terminated

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)

Parkinson's Disease

China
Boehringer Ingelheim

Completed

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Healthy

China
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Alexion Pharmaceuticals, Inc.

Completed

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany
Boehringer Ingelheim

Completed

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Austria
Boehringer Ingelheim

Completed

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

Tourette Syndrome

United States, Germany
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Pfizer

Completed

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

Biological Availability

United States
Pfizer

Completed

Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations

Healthy Participants

Belgium
Boehringer Ingelheim

Completed

Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers

Healthy
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Boehringer Ingelheim

Completed

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Healthy
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Guang'anmen Hospital of China Academy of Chinese...

Unknown

Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris

Coronary Heart Disease | Stable Angina
Velicept Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Overactive Bladder

United States
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Diurnal Limited
National Institutes of Health Clinical Center (CC)

Completed

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

Adrenogenital Syndrome | Congenital Adrenal Hyperplasia | 21-Hydroxylase Deficiency

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.

Idiopathic Restless Legs Syndrome

Japan
Sarfez Pharmaceuticals, Inc.
Sarfez Pharmaceuticals, Inc.

Recruiting

Immediate Release Versus Extended Release Torsemide After Salty Meal

Heart Failure

United States
Overseas Pharmaceuticals, Ltd.
Virginia Contract Research Organization Co., Ltd.

Terminated

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers

Pain Control

Taiwan
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

HIV Infections

United States, South Africa, Thailand, Botswana
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A SHR0302 BA Study on Healthy Subjects

Autoimmune Diseases

China
Yungjin Pharm. Co., Ltd.
Chonbuk National University Hospital

Completed

Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination

Pain
Boehringer Ingelheim

Completed

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

Healthy

3

Subscribe